Chemotherapy-Induced Ovarian Failure

[1]  L. Rutqvist,et al.  Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  P. Ganz,et al.  Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial. , 2004, Journal of the National Cancer Institute.

[3]  R. Langer,et al.  Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. , 2003, JAMA.

[4]  R. Eastell.  Management of osteoporosis due to ovarian failure. , 2003, Medical and pediatric oncology.

[5]  R. Langer,et al.  Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women: The Women's Health Initiative Randomized Trial , 2003 .

[6]  P. Porter,et al.  Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. , 2003, JAMA.

[7]  L. Hartmann,et al.  Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. , 2003, The New England journal of medicine.

[8]  J. Stephenson.  FDA Orders Estrogen Safety Warnings , 2003 .

[9]  J. Benson,et al.  Update on clinical role of tamoxifen , 2003, Current opinion in obstetrics & gynecology.

[10]  K. Kieburtz,et al.  Gabapentin's Effects on Hot Flashes in Postmenopausal Women: A Randomized Controlled Trial , 2003, Obstetrics and gynecology.

[11]  Y. Miyoshi,et al.  Influence of adjuvant tamoxifen treatment on bone mineral density and bone turnover markers in postmenopausal breast cancer patients in Japan. , 2002, Cancer letters.

[12]  P. Wingo,et al.  Hormone Replacement Therapy Regimens and Breast Cancer Risk , 2002 .

[13]  P. Novotny,et al.  Depomedroxyprogesterone acetate for hot flashes. , 2002, Journal of pain and symptom management.

[14]  E. Vittinghoff,et al.  Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). , 2002, JAMA.

[15]  E. Perez,et al.  Pilot evaluation of gabapentin for treating hot flashes. , 2002, Mayo Clinic proceedings.

[16]  A. Clouston,et al.  Black cohosh and other herbal remedies associated with acute hepatitis , 2002, The Medical journal of Australia.

[17]  E. Vittinghoff,et al.  Cardiovascular outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II) , 2002 .

[18]  E. Vittinghoff,et al.  Noncardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-Up (HERS II) , 2002 .

[19]  V. Beral,et al.  Evidence from randomised trials on the long-term effects of hormone replacement therapy , 2002, The Lancet.

[20]  G. Rodan,et al.  Bisphosphonate mechanism of action , 2002, Current molecular medicine.

[21]  J. Reginster,et al.  Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. , 2002, The Journal of clinical endocrinology and metabolism.

[22]  P. Hartge,et al.  Menopausal hormone replacement therapy and risk of ovarian cancer. , 2002, JAMA.

[23]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[24]  Deborah Grady,et al.  Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). , 2002, JAMA.

[25]  Stephen B. Hulley,et al.  Noncardiovascular disease outcomes during 6.8 years of hormone therapy : Heart and Estrogen/Progestin Study fellow-up (HERS II) , 2002 .

[26]  J. Cuzick,et al.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.

[27]  P. Sismondi,et al.  Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  J. Rossouw.  Effect of postmenopausal hormone therapy on cardiovascular risk. , 2002, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[29]  A. Algra,et al.  Oral contraceptives and the risk of myocardial infarction. , 2001, European heart journal.

[30]  B. Vastag.  Hormone replacement therapy falls out of favor with expert committee. , 2002, JAMA.

[31]  E. Weiderpass,et al.  Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. , 2002, Journal of the National Cancer Institute.

[32]  J. Rowe,et al.  Fertility after treatment for Hodgkin's disease. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  E. Perez,et al.  Phase III evaluation of fluoxetine for treatment of hot flashes. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  G. K. Chambers,et al.  Effect of Soy Phytoestrogens on Hot Flashes in Postmenopausal Women With Breast Cancer: A Randomized, Controlled Clinical Trial , 2002 .

[35]  R. Pazdur,et al.  Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  E. Baracat,et al.  Benefits of Soy Isoflavone Therapeutic Regimen on Menopausal Symptoms , 2002, Obstetrics and gynecology.

[37]  M. Dowsett,et al.  Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  P. Newcomb,et al.  Hormone replacement therapy in relation to breast cancer. , 2002, JAMA.

[39]  E. Vittinghoff,et al.  Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. , 2002, JAMA.

[40]  P. Ganz,et al.  Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. , 2002, Journal of the National Cancer Institute.

[41]  Bea C Tanis.  Contraceptivos orales y riesgo de infarto de miocardio , 2001 .

[42]  P. Ganz.  Impact of tamoxifen adjuvant therapy on symptoms, functioning, and quality of life. , 2001, Journal of the National Cancer Institute. Monographs.

[43]  P. Jacobsen,et al.  Sexual functioning in breast cancer survivors. , 2001, Cancer control : journal of the Moffitt Cancer Center.

[44]  V. Jordan,et al.  Tamoxifen to raloxifene and beyond. , 2001, Seminars in oncology.

[45]  P. Sjödén,et al.  Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: a prospective randomized study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  A. Neugut,et al.  Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  H. Hollema,et al.  TAMOXIFEN TREATMENT AND GYNECOLOGIC SIDE EFFECTS: A REVIEW , 2001, Obstetrics and gynecology.

[48]  J. Simon.  Safety of estrogen/androgen regimens. , 2001, The Journal of reproductive medicine.

[49]  A. Tumber,et al.  Human breast‐cancer cells stimulate the fusion, migration and resorptive activity of osteoclasts in bone explants , 2001, International journal of cancer.

[50]  Shiaw‐Der Yang,et al.  Suppression of proline‐directed protein kinase FA systemically inhibits the growth of human acute leukemia cells , 2001, International journal of cancer.

[51]  P. Ganz,et al.  Factors related to sexual function in postmenopausal women with a history of breast cancer , 2001, Menopause.

[52]  Susan R. Johnson,et al.  Osteoporosis prevention, diagnosis, and therapy. , 2001, JAMA.

[53]  S. Davis,et al.  Testosterone influences libido and well being in women , 2001, Trends in Endocrinology & Metabolism.

[54]  E. Briganti,et al.  The effects of Chinese medicinal herbs on postmenopausal vasomotor symptoms of Australian women , 2001, The Medical journal of Australia.

[55]  Debra L Barton,et al.  Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial , 2000, The Lancet.

[56]  H. Arnesen,et al.  Increased Risk of Recurrent Venous Thromboembolism during Hormone Replacement Therapy , 2000, Thrombosis and Haemostasis.

[57]  D. Meirow.  Reproduction post-chemotherapy in young cancer patients , 2000, Molecular and Cellular Endocrinology.

[58]  A. Vincent,et al.  Soy isoflavones: are they useful in menopause? , 2000, Mayo Clinic proceedings.

[59]  Orman,et al.  Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. , 2000, The New England journal of medicine.

[60]  M. Espié,et al.  Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy , 2000, British Journal of Cancer.

[61]  P. Ganz,et al.  Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. , 2000, Journal of the National Cancer Institute.

[62]  R. Lobo,et al.  Vasomotor Symptom Relief by Soy Isoflavone Extract Tablets in Postmenopausal Women: A Multicenter, Double‐Blind, Randomized, Placebo‐Controlled Study , 2000, Menopause.

[63]  G. Lyman,et al.  Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer. , 2000, Journal of pain and symptom management.

[64]  J. Lenihan,et al.  Initial 17β‐Estradiol Dose for Treating Vasomotor Symptoms , 2000, Obstetrics and gynecology.

[65]  B. Walsh,et al.  Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. , 2000, The Journal of clinical endocrinology and metabolism.

[66]  J. Pfeilschifter,et al.  Osteoporosis due to cancer treatment: pathogenesis and management. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  S. Coughlin,et al.  A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. , 2000, Journal of clinical epidemiology.

[68]  P. Novotny,et al.  Tamoxifen-induced hot flashes. , 2000, Clinical breast cancer.

[69]  P. Novotny,et al.  Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  A. Riva,et al.  Clinical Effects of a Standardized Soy Extract in Postmenopausal Women: A Pilot Study , 2000, Menopause.

[71]  E. Vittinghoff,et al.  Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study , 2000, Annals of Internal Medicine.

[72]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[73]  S. Shalet,et al.  Fertility after treatment for cancer , 1999, BMJ.

[74]  S. Devesa,et al.  Cancer prevalence and survivorship issues: analyses of the 1992 National Health Interview Survey. , 1999, Journal of the National Cancer Institute.

[75]  J. Rowe,et al.  Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. , 1999 .

[76]  C C Glüer,et al.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.

[77]  F. Pansini,et al.  Dietary soy supplementation and phytoestrogen levels. , 1999, Obstetrics and gynecology.

[78]  P. Ganz,et al.  Predictors of sexual health in women after a breast cancer diagnosis. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  D. Meirow,et al.  Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool. , 1999, Human reproduction.

[80]  R. Cody,et al.  Subtle Differences in Quality of Life After Breast Cancer Surgery , 1999, Annals of Surgical Oncology.

[81]  J. Baty,et al.  Effect of tamoxifen on sexual functioning in patients with breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  J. Mönkkönen,et al.  Molecular mechanisms of action of bisphosphonates. , 1999, Bone.

[83]  T. Spector,et al.  A high incidence of vertebral fracture in women with breast cancer , 1999, British Journal of Cancer.

[84]  A. LaCroix,et al.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.

[85]  N. Klein,et al.  Endocrine changes of the perimenopause. , 1998, Clinical obstetrics and gynecology.

[86]  Susan R. Johnson,et al.  Symptom Relief and Side Effects of Postmenopausal Hormones: Results From the Postmenopausal Estrogen/Progestin Interventions Trial , 1998, Obstetrics and gynecology.

[87]  J. Brisson,et al.  Type of mastectomy and quality of life for long term breast carcinoma survivors , 1998, Cancer.

[88]  J. Sloan,et al.  Definitions of hot flashes in breast cancer survivors. , 1998, Journal of pain and symptom management.

[89]  J. Flaws,et al.  Predictors of menopausal hot flashes. , 1998, Journal of women's health.

[90]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[91]  K. Kerlikowske,et al.  HORMONE REPLACEMENT THERAPY AND THE RISK OF EPITHELIAL OVARIAN CARCINOMA: A META‐ANALYSIS , 1998, Obstetrics and gynecology.

[92]  E. Vittinghoff,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[93]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[94]  T. Powles,et al.  Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. , 1998, Journal of the National Cancer Institute.

[95]  M. Cordova,et al.  Hot flashes in postmenopausal women treated for breast carcinoma , 1998, Cancer.

[96]  J. Sloan,et al.  Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes , 1998, Cancer.

[97]  P. Wingo,et al.  Long-term cancer patient survival in the United States. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[98]  C. Christiansen,et al.  Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. , 1998 .

[99]  P. Delmas,et al.  Bone loss induced by cancer treatment and its management. , 1998, European journal of cancer.

[100]  P. Novotny,et al.  Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  P. Ganz,et al.  Life after breast cancer: understanding women's health-related quality of life and sexual functioning. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  L. Zanotti,et al.  The Effect of Dietary Soy Supplementation on Hot Flushes , 1998, Obstetrics and gynecology.

[103]  W. Jee,et al.  Effects of short‐term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: A comparative histomorphometric study on the cancellous bone formed before, during, and after treatment , 1997, The Anatomical record.

[104]  L. Mariani,et al.  The aromatase inhibitor letrozole in advanced breast cancer: Effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels , 1997, The Journal of Steroid Biochemistry and Molecular Biology.

[105]  H. Genant,et al.  Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. , 1997, The American journal of medicine.

[106]  G E Dallal,et al.  Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. , 1997, The New England journal of medicine.

[107]  A. Moyer,et al.  Psychosocial outcomes of breast-conserving surgery versus mastectomy: a meta-analytic review. , 1997, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[108]  Ego Seeman,et al.  Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. , 1997, JAMA.

[109]  P. Delmas,et al.  Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  J. Sloan,et al.  Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  S. Barni,et al.  Sexual dysfunction in treated breast cancer patients. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[112]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[113]  T. Powles,et al.  Clodronate decreases the frequency of skeletal metastases in women with breast cancer. , 1996, Bone.

[114]  S. Young-McCaughan.  Sexual functioning in women with breast cancer after treatment with adjuvant therapy. , 1996, Cancer nursing.

[115]  S. Cox,et al.  Transplantation of cryopreserved fetal ovarian tissue to adult recipients in mice. , 1996, Journal of reproduction and fertility.

[116]  M. Cobleigh,et al.  Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  I. Reid,et al.  The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. , 1995, The American journal of medicine.

[118]  J Dequeker,et al.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. , 1995, The New England journal of medicine.

[119]  I. Reid,et al.  Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. , 1995, The American journal of medicine.

[120]  E. Lawrence,et al.  Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. , 1995, Biology of reproduction.

[121]  J. Kanis,et al.  Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report , 1994, Osteoporosis International.

[122]  J. O'fallon,et al.  Megestrol acetate for the prevention of hot flashes. , 1994, The New England journal of medicine.

[123]  R. Prince.  Counterpoint: estrogen effects on calcitropic hormones and calcium homeostasis. , 1994, Endocrine reviews.

[124]  R. Webb,et al.  Restoration of fertility to oophorectomized sheep by ovarian autografts stored at-196°C , 1994 .

[125]  J. O'fallon,et al.  Transdermal clonidine for ameliorating post-orchiectomy hot flashes. , 1994, The Journal of urology.

[126]  G. Stoica,et al.  Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[127]  P. Motta,et al.  Ultrastructure of human ovarian primordial follicles after combination chemotherapy for Hodgkin's disease. , 1993, Human reproduction.

[128]  K. McPherson,et al.  Measuring the impact of menopausal symptoms on quality of life. , 1993, BMJ.

[129]  A. Meadows,et al.  Late effects of childhood cancer therapy. , 1993, Current problems in pediatrics.

[130]  F Duboeuf,et al.  Vitamin D3 and calcium to prevent hip fractures in elderly women. , 1992, The New England journal of medicine.

[131]  C. Webber,et al.  Psychosocial adjustment in post-menopausal women. , 1992, The Canadian journal of nursing research = Revue canadienne de recherche en sciences infirmieres.

[132]  P. Ganz,et al.  Breast conservation versus mastectomy. Is there a difference in psychological adjustment or quality of life in the year after surgery? , 1992, Cancer.

[133]  R B Mazess,et al.  Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. , 1992, The New England journal of medicine.

[134]  A. Flanagan,et al.  Inhibition of bone resorption by bisphosphonates: Interactions between bisphosphonates, osteoclasts, and bone , 1991, Calcified Tissue International.

[135]  J. Rosenberg,et al.  Hypothesis: pathogenesis of postmenopausal hot flush. , 1991, Medical hypotheses.

[136]  J. de Haes,et al.  The impact of breast-conserving treatment and mastectomy on the quality of life of early-stage breast cancer patients: a review. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[137]  M Baum,et al.  Psychological outcomes of different treatment policies in women with early breast cancer outside a clinical trial. , 1990, BMJ.

[138]  A. Hart,et al.  Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. , 1990, British Journal of Cancer.

[139]  K. Moghissi,et al.  Chemotherapy-induced premature ovarian failure: Mechanisms and prevention , 1989, Steroids.

[140]  R. Lindsay,et al.  Estrogen in Prevention and Treatment of Osteoporosis a , 1989, Annals of the New York Academy of Sciences.

[141]  R. Mazess,et al.  Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years , 1988, Breast Cancer Research and Treatment.

[142]  M. Hammar,et al.  Climacteric symptoms among women aged 60-62 in Linköping, Sweden, in 1986. , 1988, Maturitas.

[143]  D. Longo,et al.  Late complications of curative treatment in Hodgkin's disease. , 1988, JAMA.

[144]  H. B. Marsden,et al.  Improvements in survival from childhood cancer: results of a population based survey over 30 years , 1988, British medical journal.

[145]  G. Tajchner,et al.  Veralipride: alternative antidopaminergic treatment for menopausal symptoms. , 1988, American journal of obstetrics and gynecology.

[146]  S. Rivkees,et al.  The relationship of gonadal activity and chemotherapy-induced gonadal damage. , 1988, JAMA.

[147]  L. Strong,et al.  Effects of treatment on fertility in long-term survivors of childhood or adolescent cancer. , 1987 .

[148]  J A Downey,et al.  Thermoregulatory physiology of menopausal hot flashes: a review. , 1987, Canadian journal of physiology and pharmacology.

[149]  C. Shih,et al.  Study of histomorphometric changes of the mandibular condyles in neonatal and juvenile rats after administration of cyclophosphamide. , 1986, Acta anatomica.

[150]  W. LeMaire,et al.  A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. , 1985, Cancer research.

[151]  R. Casper,et al.  NEUROENDOCRINOLOGY OF MENOPAUSAL FLUSHES: AN HYPOTHESIS OF FLUSH MECHANISM , 1985, Clinical endocrinology.

[152]  R. Baron,et al.  Effects of chemotherapeutic agents on bone. I. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rat model. , 1984, The Journal of bone and joint surgery. American volume.

[153]  R. Lobo,et al.  Depo‐Medroxyprogesterone Acetate Compared With Conjugated Estrogens for the Treatment of Postmenopausal Women , 1984, Obstetrics and gynecology.

[154]  R. Chapman.  Effect of cytotoxic therapy on sexuality and gonadal function. , 1982, Seminars in oncology.

[155]  L. M. Glodé,et al.  PROTECTION FROM CYCLOPHOSPHAMIDE-INDUCED TESTICULAR DAMAGE WITH AN ANALOGUE OF GONADOTROPIN-RELEASING HORMONE , 1981, The Lancet.

[156]  S. Sutcliffe,et al.  Cytotoxic-induced ovarian failure in women with Hodgkin's disease. I. Hormone function. , 1979, JAMA.

[157]  R. Lindsay,et al.  BONE RESPONSE TO TERMINATION OF OESTROGEN TREATMENT , 1978 .

[158]  R. Lindsay,et al.  BONE RESPONSE TO TERMINATION OF ŒSTROGEN TREATMENT , 1978, The Lancet.

[159]  G. Malkasian,et al.  Endometrial Cancer Associated With Feminizing Ovarian Tumor and Polycystic Ovarian Disease , 1977, Obstetrics and gynecology.

[160]  D. Thompson,et al.  Association of exogenous estrogen and endometrial carcinoma. , 1975, The New England journal of medicine.

[161]  S. Mckinlay,et al.  The menopausal syndrome , 1974, British journal of preventive & social medicine.

[162]  C. Christiansen,et al.  Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy , 2005, Osteoporosis International.

[163]  Patricia A. Ganz,et al.  Breast cancer survivors: Psychosocial concerns and quality of life , 2005, Breast Cancer Research and Treatment.

[164]  Claus Christiansen,et al.  Consensus development conference: Prophylaxis and treatment of osteoporosis , 2005, Osteoporosis International.

[165]  M. Stockler,et al.  Bisphosphonates for breast cancer. , 2005, The Cochrane database of systematic reviews.

[166]  H. Heimpel,et al.  Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapy for Hodgkin's disease , 2004, Journal of Cancer Research and Clinical Oncology.

[167]  G. Dinant,et al.  Risk Factors for Osteoporosis Related to their Outcome: Fractures , 2001, Osteoporosis International.

[168]  S. Martino,et al.  Double blind phase III trial of placebo (P) vs. megestrol acetate (MA) 20 mg vs. MA 40 mg as treatment for symptoms of ovarian failure in breast cancer survivors: Initial results of Southwest Oncology Group S9626 , 2001 .

[169]  J. Hanfelt,et al.  A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[170]  B. Hillner,et al.  Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[171]  B. Campbell,et al.  Long-term ovarian function in sheep after ovariectomy and transplantation of autografts stored at -196 C. , 1999, Endocrinology.

[172]  M. Moen,et al.  Why menopausal women do not want to take hormone replacement therapy. , 1999, Menopause.

[173]  M. Seifert,et al.  Evidence that tamoxifen preserves bone density in late postmenopausal women with breast cancer. , 1998, Acta oncologica.

[174]  E. Barrett-Connor,et al.  Hormone replacement therapy, heart disease, and other considerations. , 1998, Annual review of public health.

[175]  G. Hortobagyi,et al.  Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy. , 1998, Cancer investigation.

[176]  P. Ganz,et al.  Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors. , 1998, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[177]  C. Blomqvist,et al.  Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. , 1997, British Journal of Cancer.

[178]  A. Licata.  Bisphosphonate therapy : Management of osteoporosis, 1997 , 1997 .

[179]  T. Powles,et al.  Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[180]  S. Grundfest-Broniatowski,et al.  Partial mastectomy and breast reconstruction. A comparison of their effects on psychosocial adjustment, body image, and sexuality , 1995, Cancer.

[181]  L. Nachtigall.  Comparative study: Replens versus local estrogen in menopausal women. , 1994, Fertility and sterility.

[182]  P. Vercellini,et al.  Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment. , 1992, Gynecologic and obstetric investigation.

[183]  S. Donaldson,et al.  Gonadal status and reproductive function following treatment for Hodgkin's disease in childhood: the Stanford experience. , 1990, International journal of radiation oncology, biology, physics.

[184]  R. P. Bourguignon,et al.  Veralipride versus conjugated oestrogens: a double-blind study in the management of menopausal hot flushes. , 1984, Current medical research and opinion.